| Literature DB >> 31827413 |
Noemi Montis1, Elisabetta Cotti1, Antonio Noto2, Claudia Fattuoni3, Luigi Barberini2.
Abstract
Chronic apical abscess (CAA) is a lesion of apical periodontitis mostly characterized by areas of liquefactive necrosis with disintegrating polymorphonuclear neutrophils surrounded by macrophages. Its presence leads to local bacterial infection, systemic inflammatory response, pain, and swelling. The use of a novel approach for the study of CAA, such as metabolomics, seems to be important since it has proved to be a powerful tool for biomarkers discovery which could give novel molecular insight on CAA. So, the aim of this study was to verify the possibility to identify the metabolic fingerprint of CAA through the analysis of saliva samples. Nineteen patients were selected for this study: eleven patients affected by CAA with a sinus tract constituted the study group whereas eight patients without clinical and radiographic signs of CAA formed the healthy control group. Saliva samples were collected from each subject and immediately frozen at -80°C. Metabolomic profiles were obtained using a gas chromatography/mass spectrometry instrument. Subsequently, in order to compare the two groups, a multivariate statistical model was built that resulted to be statistically significant. The class of metabolites characterizing the CAA patients was closely related to the bacterial catabolism, tissue necrosis, and presence of a sinus tract. These preliminary results, for the first time, indicate that saliva samples analyzed by means of GC/MS metabolomics may be useful for identifying the presence of CAA, leading to new insights into this disease.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31827413 PMCID: PMC6881753 DOI: 10.1155/2019/3162063
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Clinical and demographic characteristics of patients population.
| Patient ID | Gender | Age (years) | Histopathologic diagnosis |
|---|---|---|---|
| 1 | Female | 30 | CAA |
| 2 | Male | 51 | CAA |
| 3 | Male | 33 | CAA |
| 4 | Female | 60 | CAA |
| 5 | Male | 42 | CAA |
| 6 | Female | 68 | CAA |
| 7 | Male | 43 | CAA |
| 8 | Male | 39 | CAA |
| 9 | Male | 60 | CAA |
| 10 | Male | 46 | CAA |
| 11 | Male | 45 | CAA |
| 12 | Male | 37 | Control |
| 13 | Male | 30 | Control |
| 14 | Male | 41 | Control |
| 15 | Male | 38 | Control |
| 16 | Female | 39 | Control |
| 17 | Female | 45 | Control |
| 18 | Female | 56 | Control |
| 19 | Female | 60 | Control |
Figure 1(a) The OPLS-DA model indicated a clear separation between the groups; (b) cross validation (R2 = 0.793 Q2 = 0.358); (c) metabolic hubs mainly affected in CAA patients.
Variable influence in projection (metabolites accumulated or depleted in CAA patients sorted by trend).
| VIP: variable influence in projection | ||
|---|---|---|
| Metabolites | Trend in CAA patients | Score values sorted by trend |
| 4-Hydroxyhydrocinnamic acid | ↑ | 1.90102 |
|
| ↑ | 1.70824 |
| Inositol-like | ↑ | 1.35246 |
| Ornithine | ↑ | 1.2671 |
| Putrescine | ↑ | 1.25158 |
| Phosphoethanolamine | ↑ | 1.1257 |
| Hypoxanthine | ↑ | 1.07426 |
| 5-Aminopentanoic acid | ↑ | 0.99078 |
| Proline | ↑ | 0.948403 |
| Uracil | ↑ | 0.804598 |
| Lysine | ↑ | 0.764083 |
| Stearic acid | ↑ | 0.698099 |
| Threonine | ↑ | 0.654658 |
| Uric acid | ↑ | 0.630694 |
| Glycine | ↑ | 0.620945 |
| Sorbitol | ↓ | 4.42798 |
| Maltose | ↓ | 3.66992 |
| Glucose | ↓ | 2.58188 |
| Xylitol | ↓ | 1.74627 |
| Succinic acid | ↓ | 1.26194 |
| Ethanolamine | ↓ | 1.17785 |
| Lactic acid | ↓ | 1.13476 |
| Palmitic acid | ↓ | 1.02905 |
| Citric acid | ↓ | 0.995201 |
| Urea | ↓ | 0.886784 |
| 1,2-Propanediol | ↓ | 0.774375 |
| meso-2,3-butanediol | ↓ | 0.67866 |
Most important pathways based on the metabolic fingerprint.
| Pathways mainly affected in CAA patients | |||
|---|---|---|---|
| Pathway name |
| False discovery rate (FDR) | Metabolites belonging to the pathway |
| Purine nucleotide cycle | 0,004 | 0,125 | Hypoxanthine, urea, uric acid, glycine, inositol, urea, 1,2-propanediol |
| Amino sugar and nucleotide sugar metabolism | 0,009 | 0,125 | Glucose, pyruvic acid, |
| Pentose phosphate pathway | 0,009 | 0,125 | Glucose, pyruvic acid, phosphate, ethanolamine |
| Glycolysis and gluconeogenesis pathways | 0,022 | 0,242 | Lactic acid, pyruvic acid, glucose, citric acid, succinic acid |